Credit Suisse (SIX:CSGN) analyst Jailendra Singh maintained a Buy rating on Livongo Health (NASDAQ:LVGO) on Friday, setting a price target of $132, which is approximately 0.28% below the present share price of $132.37.
Singh expects Livongo Health to post earnings per share (EPS) of -$0.02 for the third quarter of 2020.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Livongo Health, with an average price target of $119.2.
The analysts price targets range from a high of $155 to a low of $70.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $91.92 million and a net profit of -$260 thousand. The company's market cap is $13.45 billion.
According to TipRanks.com, Credit Suisse analyst Jailendra Singh is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.6% and a 45.45% success rate.
Livongo Health, Inc. develops and operates a consumer digital health platform that provides smart, cellular-connected devices, supplies, informed coaching, data science-enabled insights and facilitates access to medications across multiple chronic conditions. It focuses on diabetes, hypertension, weight management, diabetes prevention, and behavioral health. The company was founded by Kimon Angelides and Glen E. Tullman on October 16, 2008 and is headquartered in Mountain View, CA.